Is AOD-9604 Legal in North Carolina? How to Access It Legally

What Is AOD-9604 and Why Does Its Legal Status Matter?

AOD-9604 is a synthetic fragment of human growth hormone (hGH), specifically the C-terminal amino acid sequence from positions 176 to 191. Researchers originally developed it at Monash University in Australia as a weight-management compound that might replicate hGH's fat-metabolizing properties without causing insulin resistance or stimulating IGF-1. Legal status matters here because the compound is neither a licensed pharmaceutical product in the United States nor a simple dietary supplement.

The Compound's Clinical Background

Early animal studies showed that AOD-9604 reduced fat mass in obese rodents without the pro-diabetic effects of full-length hGH. A Phase IIb trial registered with the Australian government (Metabolic Pharmaceuticals, now discontinued) tested oral AOD-9604 in overweight adults and found modest but statistically detectable reductions in body weight over 12 weeks. However, the compound never advanced to a Phase III trial that could support FDA New Drug Application (NDA) approval, leaving it outside the mainstream drug-approval pipeline entirely.

Why the Gray Area Exists

Because AOD-9604 has documented human pharmacology and was once in active clinical development, it does not fit cleanly into the "research chemical" category. It is also not an FDA-approved drug, not a scheduled controlled substance under the DEA's schedules, and not a recognized dietary supplement ingredient under 21 U.S.C. § 321(ff). That three-way gap is the source of the legal complexity. Physicians, pharmacies, and patients who want to use it must manage FDA compounding law rather than conventional drug-prescribing rules. [1]

The Federal Regulatory Framework That Controls AOD-9604 Access

Federal law, not North Carolina state law, sets the outer boundary of what is permissible with AOD-9604. Two sections of the Food, Drug, and Cosmetic Act are most relevant: Section 503A (governing traditional compounding pharmacies that prepare patient-specific prescriptions) and Section 503B (governing outsourcing facilities that produce sterile compounds at larger scale). [2]

Section 503A and the Bulk-Drug Nominee List

Under Section 503A, a compounding pharmacy may use a bulk drug substance only if it appears on an FDA-approved list, if it is a component of an FDA-approved drug, or if it is a substance that is used in a United States Pharmacopeia (USP) or National Formulary (NF) monograph. AOD-9604 does not meet any of those three criteria.

The FDA evaluated AOD-9604 as a bulk-drug nominee for 503A compounding. In its 2023 published evaluations, the agency concluded that AOD-9604 presents "safety risks" and lacks "a clinical need that cannot be met by an FDA-approved drug." As a result, AOD-9604 was placed on Category 2 of the 503A bulk-drug list, which effectively prohibits traditional compounding pharmacies from preparing it for patient prescriptions. [3]

That Category 2 designation is the single most consequential regulatory fact for any North Carolina patient or provider asking about AOD-9604. It means that the most common route through which peptides like BPC-157 or sermorelin reach patients as compounded preparations is simply not available for AOD-9604.

Section 503B Outsourcing Facilities

503B outsourcing facilities can compound drugs without patient-specific prescriptions for distribution to healthcare providers, but they are restricted to using bulk substances that appear on a separate FDA-approved 503B list. AOD-9604 does not appear on that list either. [4] No licensed 503B facility in the United States may therefore legally produce AOD-9604 for clinical distribution.

The IND Research Pathway

One narrow federal pathway remains open. A licensed researcher or institution may obtain an Investigational New Drug (IND) application from the FDA under 21 C.F.R. Part 312, which would permit use of AOD-9604 in a supervised clinical trial setting. This pathway requires an approved protocol, an Institutional Review Board (IRB), informed consent procedures, and ongoing FDA oversight. It is not a practical route for individual patients seeking the compound for personal weight management. [5]

North Carolina State Law: What the NCMB and Pharmacy Board Add

North Carolina has no statute specifically naming or prohibiting AOD-9604. The compound's accessibility in the state is determined almost entirely by the federal framework described above, filtered through two state licensing bodies.

North Carolina Medical Board (NCMB)

The NCMB licenses and disciplines physicians under G.S. Chapter 90, Article 1. The Board does not maintain a peptide-specific prescribing policy, but it does expect physicians to prescribe only substances that can be lawfully dispensed and that have a reasonable evidence base for the intended use. A physician who writes a prescription for AOD-9604 knowing that no licensed pharmacy can legally fill it may face Board scrutiny for facilitating unlicensed drug distribution, even if no criminal statute is directly implicated.

The NCMB's 2022 policy statement on non-FDA-approved therapies notes that "prescribing or ordering a drug or device for a purpose not approved by the FDA is permissible if the physician relies upon sound medical evidence, documents the clinical rationale, and discloses the off-label status to the patient." [6] That standard technically applies to off-label FDA-approved drugs, not to bulk substances that a pharmacy cannot legally compound, so it provides limited cover for AOD-9604 prescribing.

North Carolina Board of Pharmacy

The North Carolina Board of Pharmacy (NCBOP) regulates all compounding pharmacies operating in the state under G.S. Chapter 90, Article 4A. NCBOP-licensed pharmacies must follow both state rules and federal law, including the 503A restrictions on bulk substances. A North Carolina compounding pharmacy that prepares AOD-9604 for a patient prescription is at risk of violating federal law, which NCBOP takes into account in licensing and disciplinary proceedings. [7]

Some pharmacies in adjacent states or operating through mail-order arrangements have continued to offer AOD-9604. Patients in North Carolina who receive such shipments are receiving a product that was likely compounded outside the legal 503A framework, regardless of which state the pharmacy is physically located in.

Practical Access Pathways in North Carolina Today

Given the federal restrictions, what options genuinely exist for a North Carolina resident who wants AOD-9604?

The table below summarizes the four pathways, rated by current legal standing:

| Pathway | Legal Standing | Practical Availability | |---|---|---| | 503A compounding pharmacy | Not permitted (Category 2) | No | | 503B outsourcing facility | Not on 503B list | No | | FDA IND / clinical trial | Permitted with full FDA oversight | Research settings only | | Direct online purchase (unregulated) | Violates FD&C Act; no physician oversight | Available but illegal and unsafe |

Telehealth Platforms and Peptide Clinics

A number of telehealth platforms and men's health clinics advertise "peptide therapy" panels in North Carolina. Some list AOD-9604 by name. Given the 2023 Category 2 determination, any clinic or telehealth service actively dispensing compounded AOD-9604 to North Carolina patients is doing so outside the current legal framework for compounding pharmacies, regardless of how the service is marketed.

Patients should ask any telehealth provider two direct questions before proceeding: (1) which pharmacy will fill the prescription, and (2) is that pharmacy operating under a valid 503A or 503B authorization for this specific substance. If the provider cannot answer both questions clearly, that is a signal that the supply chain may not be compliant.

What a Compliant Provider Encounter Looks Like

A physician in North Carolina can legally discuss AOD-9604 with a patient, document the clinical rationale (typically weight management or body composition in the context of obesity or metabolic syndrome), and explain that no currently licensed compounding pathway exists for the compound. The physician may then offer alternative peptides or pharmacological agents that are legally available.

For weight management specifically, FDA-approved options include semaglutide 2.4 mg (Wegovy), which in the STEP-1 trial (N=1,961) produced a 14.9% mean reduction in body weight at 68 weeks compared with 2.4% in the placebo group (P<0.001). [8] Tirzepatide 15 mg (Zepbound) produced a 20.9% mean weight loss at 72 weeks in the SURMOUNT-1 trial (N=2,539). [9] These are FDA-approved alternatives with Phase III safety data that AOD-9604 currently lacks.

Sermorelin and tesamorelin are growth hormone secretagogues with clearer compounding pathways that some physicians substitute when patients are specifically interested in growth hormone axis peptides.

Safety Considerations for AOD-9604 Purchased Outside Legal Channels

Patients who purchase AOD-9604 from unregulated online vendors face risks beyond the legal ones.

Product Purity and Identity

The FDA has issued multiple Warning Letters to manufacturers of unregulated peptide products citing failures in sterility, potency, and identity testing. A 2020 FDA laboratory analysis of peptide products purchased online found that fewer than half contained the labeled active substance at the stated concentration, and several contained bacterial endotoxins at levels that would disqualify them from injection use. [10] AOD-9604 is typically administered by subcutaneous injection, meaning contamination risk is direct.

Absence of Clinical Dosing Data

No Phase III trial has established a safe or effective dose range for AOD-9604 in humans. The Phase IIb Australian data used oral dosing at 1 mg/day, a route and dose that may differ substantially from the injectable formulations sold online. Extrapolating from animal studies to human subcutaneous dosing is not validated by current evidence. Patients self-administering injectable AOD-9604 without physician supervision are operating without a clinical safety net.

Interaction With GH Axis Testing

Physicians who manage patients on growth hormone therapies routinely monitor IGF-1 levels and occasionally perform stimulation testing. AOD-9604 may interfere with the interpretation of these tests even if its direct IGF-1 stimulatory effect is minimal, because the fragment shares antigenic regions with full-length hGH. A patient who does not disclose AOD-9604 use to their endocrinologist or primary care physician risks misinterpretation of GH axis testing results. [11]

How to Talk to a North Carolina Provider About AOD-9604

Transparency with your prescribing physician is the most practical protective step a patient can take. A physician who is aware of a patient's interest in AOD-9604 can document the conversation, counsel on alternatives, monitor for adverse effects if the patient proceeds independently, and adjust other medication management accordingly.

Finding a Peptide-Familiar Provider in NC

North Carolina has a growing number of physicians trained in functional and metabolic medicine who are familiar with peptide pharmacology. The American Academy of Anti-Aging Medicine (A4M) maintains a provider directory that includes NC-licensed physicians with peptide training, though directory listings do not guarantee any specific prescribing practice. Endocrinologists affiliated with UNC Health, Duke Health, and Atrium Health Wake Forest Baptist are trained to manage complex weight and GH-axis disorders and may be appropriate referral options when peptide inquiries arise alongside clinical metabolic concerns.

What to Bring to the Appointment

Arriving with documentation of weight history, prior pharmacological treatments tried, and any labs (fasting glucose, HbA1c, lipid panel, IGF-1 if available) gives the provider enough clinical context to make a reasoned treatment recommendation. Patients who present with a BMI <27 and no documented metabolic comorbidity are less likely to have a physician-supported rationale for any weight-loss peptide, including FDA-approved agents.

Documentation and Informed Consent

If a provider agrees to supervise a patient's AOD-9604 use obtained through a non-compliant channel (rare, but possible in direct-care or membership-based practices operating outside insurance billing), the provider should document the experimental status of the compound, the absence of Phase III human data, the patient's understanding of legal restrictions, and a monitoring plan that includes at minimum baseline and follow-up metabolic labs. The FDA's guidance on "unapproved drugs" does not criminalize patient possession of a non-controlled substance for personal use, but it does not protect the prescribing or dispensing provider who facilitates access through an unlicensed supply chain. [12]

The Regulatory Outlook: Could This Change?

The FDA's 2023 Category 2 determination is not permanent statute. It is an agency evaluation that can be revised if new evidence is submitted through the public docket process. A pharmaceutical company or academic institution could submit a revised GRAS (generally recognized as safe) nomination or a new NDA for AOD-9604, potentially reopening the 503A pathway.

The peptide research space is moving quickly. The FDA finalized its 503A bulks framework after years of notice-and-comment rulemaking, and additional peptides are under evaluation for both the positive (Category 1, permitted) and negative (Category 2, prohibited) lists. Staying current with the FDA's pharmacy compounding advisory committee (PCAC) meeting minutes is the most reliable way to track whether AOD-9604's status changes. Those minutes are published at fda.gov under the pharmacy compounding section. [13]

For North Carolina patients and providers, the practical recommendation as of mid-2025 is to treat AOD-9604 as legally inaccessible through licensed pharmacies, to document any clinical rationale thoroughly, and to consider FDA-approved GLP-1 receptor agonists or legally compoundable peptides (sermorelin, ipamorelin/CJC-1295 if on the 503A positive list) as the primary pharmacological options for weight and body-composition goals. Patients interested in the science of hGH-fragment therapies may also consider participating in registered clinical trials by searching ClinicalTrials.gov for active AOD-9604 studies, as trial participation remains the only fully protected route to accessing investigational compounds. [5]